Concept:
Alzheimer's disease is a progressive neurodegenerative disorder characterized pathologically by extracellular amyloid-beta ($\beta$-amyloid) plaques and intracellular neurofibrillary tau tangles, alongside a severe loss of central cholinergic neurons in the basal forebrain.
Therapeutic management focuses on two strategies:
• Reversible Acetylcholinesterase Inhibitors: Boost acetylcholine levels in the synaptic cleft (e.g., Donepezil, Galantamine, Rivastigmine).
• Monoclonal Antibodies targeting Amyloid: Clear $\beta$-amyloid deposits (e.g., Aducanumab, Lecanemab).
Step 1: Evaluate the role of Carbamazepine.
Carbamazepine is a sodium channel blocker widely categorized as an antiepileptic drug (anticonvulsant) used to manage generalized tonic-clonic seizures, partial seizures, and neuropathic pain conditions like trigeminal neuralgia. It does not target Alzheimer's pathology, making it the correct choice.